Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.

@article{Simon2011ClinicalEA,
  title={Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.},
  author={Tabassome Simon and Philippe Gabriel Steg and Martine Gilard and Didier Blanchard and Laurent Bonello and Michel Hanssen and Herv{\'e} Lardoux and Pierre Coste and Thierry Lefevre and Elodie Drouet and Genevi{\`e}ve Mulak and Vincent Bataille and Jean Ferri{\`e}res and C{\'e}line Verstuyft and Nicolas Danchin},
  journal={Circulation},
  year={2011},
  volume={123 5},
  pages={474-82}
}
BACKGROUND Clopidogrel requires metabolic activation by cytochrome P450 2C19 (CYP2C19). Proton pump inhibitors (PPIs) that inhibit CYP2C19 are commonly coadministered with clopidogrel to reduce the risk of gastrointestinal bleeding. This analysis compares treatment outcomes for patients in the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) who did or did not receive clopidogrel and/or PPIs. METHODS AND RESULTS The FAST-MI registry included 3670… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS